Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459403 | 0.93 | PIK3CD (0.55) | POLBGPR119PIK3CD | |
| SCHEMBL21752528 | 0.87 | GPR119 (0.55) | POLBGPR119 | |
| SCHEMBL2774820 | 0.86 | GPR119 (0.54) | POLBGPR119 | |
| SCHEMBL14335009 | 0.86 | GPR119 (0.54) | POLBGPR119PIK3CD | |
| SCHEMBL2630824 | 0.86 | GPR119 (0.54) | POLBGPR119PIK3CD | |
| SCHEMBL17456002 | 0.84 | POLB (0.52) | POLBGPR119NPBWR1MCHR1PIK3CD | |
| SCHEMBL29913053 | 0.84 | GPR119 (0.52) | POLBGPR119 | |
| SCHEMBL5269296 | 0.84 | GPR119 (0.52) | POLBGPR119 | |
| SCHEMBL23311657 | 0.83 | GPR119 (0.55) | POLBGPR119 | |
| SCHEMBL23089907 | 0.83 | GPR119 (0.53) | POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | POLB 3702/4885GPR119 118/4885STS 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.